TPG GP A, LLC Form SCHEDULE 13D/A — Sep 30, 2026
TPG GP A, LLC, together with TPG executives James Coulter and Jon Winkelried, filed Amendment No. 5 to its Schedule 13D on Allogene Therapeutics disclosing a complete exit from the position. On September 28, 2026, the TPG Funds sold 18,716,306 shares of Allogene common stock at $1.55 per share pursuant to Rule 144.
Key figures
- Sale date
- 2026-09-28
- Shares sold
- 18716306
- Sale price per share
- 1.55
- Remaining stake percent
- 0
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.